ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET ...

ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET selection. Andrew L. Pecora, MD, discusses the significance of the long-term ...

Andrew L. Pecora, MD, discusses the significance of the long-term findings from the KEYNOTE-942 trial of intismeran autogene ...

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to ...

Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...

The IGNYTE continues to show promising outcomes despite negative FDA decisions.

Dr Pant highlights phase 3 data showing oral daraxonrasib nearly doubles overall survival vs chemotherapy in metastatic pancreatic cancer. The oral multi-selective inhibitor daraxonrasib significantly ...

Adaptive I-SPY 2.2 sequencing allowed surgery after Block A for predicted pCR, while nonresponders escalated to taxane then anthracycline blocks, with pembrolizumab added for immune-positive patients.

Five-year KEYNOTE-942 data show intismeran plus pembrolizumab delivers durable improvements in RFS and DMFS in high-risk resected melanoma. The mRNA-based cancer vaccine intismeran autogene combined ...

Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.

A novel treatment approach combining triple-oral metronomic chemotherapy with ultra-low-dose immunotherapy (nivolumab; TMC-I ...

APP-led benign hematology consults boost access in community oncology—cut wait times, expand capacity, and show how teams scale safely. As community oncology practices continue to face growing patient ...